---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-23-000068"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:43:22.485576+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Recursion posts Q3 net loss $93M, inks $160M Tempus data deal, restructures Bayer collaboration for oncology

## Summary
- Q3 net loss of $93.0M vs $60.4M prior year; revenue $10.5M down from $13.2M.
- Tempus 5-year data licensing deal: annual payments $22M-$42M (up to $160M total) for 20+ PB oncology data.
- Bayer collaboration refocused on oncology; up to 7 programs with aggregate milestones up to $1.5B plus royalties.
- BioHive-1 supercomputer to quadruple compute with NVIDIA H100 GPUs, expected top 50 globally by H1 2024.
- Cash $387.3M at Sept 30; pipeline on track with Phase 2 CCM and NF2 data expected H2 2024.

## SEC filing metadata
- accession: 0001601830-23-000068
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000068/0001601830-23-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000068/rxrx-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-23-000068
- JSON: https://secwatch.observer/filing/0001601830-23-000068.json
- Plain text: https://secwatch.observer/filing/0001601830-23-000068.txt

## Key facts
- Earnings Releases
  RECURSION PHARMACEUTICALS, INC. reported financial results for the third quarter ending September 30, 2023.
  - Period: the third quarter ending September 30, 2023
  - Result: reported results
  source text: On November 9, 2023, the Company issued a press release announcing its results of operations and financial condition for the third quarter September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000068/0001601830-23-000068-index.htm
- Material Agreements
  RECURSION PHARMACEUTICALS, INC. amended Restated Bayer Agreement with Bayer AG valued at Amendment and restatement of the Original Research Collaboration and Option Agreement to re-align wi (effective 2023-11-08).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Bayer AG
  - Value: Amendment and restatement of the Original Research Collaboration and Option Agreement to re-align wi
  - Effective: 2023-11-08
  source text: On November 8, 2023, the parties amended and restated the Original Bayer Agreement (the “Restated Agreement”) to re-align the Original Agreement with Bayer’s strategic shift in focus to oncology, as further described below.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000068/0001601830-23-000068-index.htm
- Material Agreements
  RECURSION PHARMACEUTICALS, INC. entered into Tempus Master Agreement with Tempus Labs, Inc. valued at Initial license fee of $22.0 million; annual fees ranging from $22.0 million to $42.0 million; total (effective 2023-11-03).
  - Action: entry
  - Counterparty: Tempus Labs, Inc.
  - Value: Initial license fee of $22.0 million; annual fees ranging from $22.0 million to $42.0 million; total
  - Effective: 2023-11-03
  source text: On November 3, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) and Tempus Labs, Inc. (“Tempus”) entered into a Master Agreement (the “Tempus Agreement”) pursuant to which Tempus may provide certain services and deliverables to Company and/or license certain data to Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601830/000160183023000068/0001601830-23-000068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.